Can China Ace The CAR-T Race?
Executive Summary
Helped by Nanjing Legend's multimillion dollar deal with J&J, China has now overtaken the US in number of clinical trials using CAR-T cell approaches to treating cancers, but could uncertainties derail the country's CAR-T train from steaming ahead?
You may also be interested in...
How China Inc. Aims To Take Over Cell Therapy Dominance
Just three years after its founding, Chinese cell therapy developer IASO Bio already has two assets in clinical development and the Nanjing firm has recently attracted $60m in financing. In an exclusive interview, its R&D head told Scrip that speed and partnerships are propelling Chinese developers on a trajectory to quickly catch up with the west in the emerging cell-therapy arena.
China CAR-T Front-Runner Allegations Reveal Soft Underbelly Of Development Race
A report from a short-seller group accuses Chinese firm Nanjing Legend of intentionally omitting clinical data for its CAR-T candidate, an allegation the company has refuted while global partner J&J says it remains "optimistic" about the product and conducted "careful" reviews of the data.
J&J Muscles Into CAR-T Field: Initiates Myeloma Studies
An autologous CAR-T therapy in development by Janssen and Legend Biotech is expected to kick-off US clinical studies in the second half of 2018, adding to the race to apply the new technology to multiple myeloma.